ELV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Elevance Health Inc (ELV) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the company's financial performance in Q4 2025 was strong, with significant growth in revenue, net income, and EPS, the technical indicators, bearish trends, and recent negative news sentiment suggest caution. Additionally, hedge funds are heavily selling, and analysts have lowered price targets, reflecting concerns about future guidance and margins. However, the stock has seen positive interest from Congress members, which could indicate confidence in its long-term potential. For now, holding the stock and monitoring for stabilization or better entry points is recommended.
The technical indicators for ELV are bearish. The MACD is negatively expanding (-5.145), the RSI is at 21.127 (neutral but close to oversold), and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels (S1: 290.081, S2: 274.596), indicating downward momentum.
Strong Q4 2025 financial performance with revenue up 9.47% YoY and EPS up 36.46% YoY.
Congress trading data shows heavy buying by members, indicating confidence in the stock.
Partnership with the National Diaper Bank Network to improve maternal and child health outcomes, which could enhance the company's social impact and brand image.
Recent negative news, including potential CMS sanctions that could halt enrollment in Medicare prescription drug plans, leading to an 8% stock drop.
Hedge funds are heavily selling, with a 135.25% increase in selling activity last quarter.
Analysts have downgraded the stock and lowered price targets due to concerns about 2026 guidance and margin outlook.
Investigations by Pomerantz LLP and Johnson Fistel, PLLP for potential securities fraud and compliance issues, respectively, which could impact investor confidence.
Elevance Health reported strong financial results for Q4 2025. Revenue increased by 9.47% YoY to $49.75 billion, net income rose by 30.86% YoY to $547 million, and EPS grew by 36.46% YoY to 2.47. These results reflect robust growth and operational efficiency.
Analyst sentiment is mixed to slightly negative. RBC Capital downgraded the stock to Sector Perform, citing softer-than-expected 2026 guidance and margin outlook. Several firms, including Truist, Barclays, and UBS, lowered price targets but maintained Buy or Overweight ratings. The average price target remains significantly above the current price, but the downward revisions reflect concerns about future performance.
